Kainat Shoukat et al



CODEN [USA]: IAJPBB

ISSN: 2349-7750

INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.2630766

Available online at: <u>http://www.iajps.com</u>

Research Article

A CASE REPORT ON FOURTEEN YEARS CHOLESTATIC HEPATITIS AFFECTED YOUNG PATIENT INDUCED BY ETHAMBUTOL

¹Dr. Kainat Shoukat, ²Dr. Numrah Nawaz, ³Dr. Mehak Yusuf

¹Shalamar Hospital Lahore.

Sharamar Hospital Eanore.				
Article Received: February 2019	Accepted: March 2019	Published: April 2019		
Abstract:				
Cholestatic hepatitis caused by ethambutol	is a well-organized complexity	which is infrequent. Its common		
identifications are vomiting, right hypochondriac heaviness. These indications may not separate t from common				
hepatocellular injury. Hepatocellular injury is usually observed during ant tuberculous therapy. Therefore, a				
comprehensive liver function test has to be carried out. This case study was related to the patient of cholestatic				
hepatitis in the age of 14 years in Pakistan. This was the first case report occurred after the beginning of ATT and				
managed when ethambutol was excluded.				
Keywords: Cholestatic, Hepatitis, Ethambuto	l, Hypochondriac, Hepatocellular,	Tuberculous, Liver and Therapy.		
Corresponding author:				
Dr. Kainat Shoukat,		QR code		
Shalamar Hospital Lahore.				
*				



Please cite this article in press Kainat Shoukat et al., A Case Report On Fourteen Years Cholestatic Hepatitis Affected Young Patient Induced By Ethambutol., Indo Am. J. P. Sci, 2019; 06(04).

INTRODUCTION:

The major anti-tuberculous drug is ethambutol. It is considered as a segment of tuberculous management approximately for 8 months. Optic neuritis is considered harmful related to its management. It may be or may not be changed [1, 2]. 1.5% is more with a dose of 25 mg/kg is the observed occurrence of optic neuritis [3]. This harmfulness is reported in many reviews and textbooks all over the medical evidence [1, 4-6]. In this report, a case of cholestatic jaundice is discussed. Its common indications are right hypochondrium heaviness and serious vomiting. After one month of anti-tuberculous therapy including ethambutol, these symptoms initiated. Before therapy and one month after therapy, the liver function tests were examined which were normal. This case was of 14 years of age which was treated at Jinnah Hospital, Lahore from March – June 2017. This case is strange in its nature.


CASE REPORT:


This case study was about a young boy whose age was fourteen years. For one week, he was suffering from right hypochondriac discomfort, lethargy and vomiting. For the previous one month, the patient was on anti-tuberculous therapy. Before treatment, his liver function test was found normal. The patient was also receiving Isoniazid, Pyrazinamide, Rifampicin and Ethambutol. The dose of Ethambutol being provided was 15 mg/kg body weight as shown in the given table.


The patient was lethargic and nervous at the time of presentation. He was found with right hypochondriac heaviness and vomiting. At the time of presentation, his weight was forty kilograms, blood pressure was 110/75 and pulse was 110/min. No other issue was observed. Anorexia was also not observed in a patient; however, the patient was febrile. The liver function tests were taken again by taking into account his indications. His Alkaline phosphatase was high as 954. While the normal level of ALT/Bilirubin was observed. Ultrasound abdomen was carried out as there was no indication of hepatocellular hepatitis. Through ultrasound, the presence of lymphadenopathy leading to cholestatic and Gamma GT Serum Test which was elevated. He was unwilling to be managed as inpatient. So, he guaranteed to get managed as an outpatient. The patient was suggested antiemetics (gravinate and famotidine). After one week, the patient again came for follow up and still found with indications. He was responsive but seems dehydrated. No history of biliary blockage was observed on ultrasound. While deranged Alkaline Phosphatase with normal ALT/Bilirubin was observed on regular LFTs. In 1985, one case of cholestatic jaundice because of ethambutol was presented. Therefore, for excluding ethambutol, ant tuberculous therapy was repeatedly carried out. Liver Function tests slowly became normal within 15 days and the patient started recovering.

Date	Bilirubin	ALT	Alk. Phosphatase
16 Mar, 17	0.64	16	207
26 Apr, 17	0.79	57	218
15 May, 17	0.94	34	954
23 May, 17	0.75	19	1031
30 May, 17	0.91	26	977
8 Jun, 17	0.73	39	243

Table: Date Wise Values of Bilirubin, ALT and Alkaline Phosphatase







DISCUSSION:

The major anti-tuberculous drug is ethambutol. It is now employed for complete management of tuberculous, as recommended by WHO. It has been reported once that Alkaline Phosphatase (ALP) was elevated by ethambutol [7]. However, all over the world, this case in this age is first reported case [6]. During anti tuberculous management, finding the reason for vomiting can lead to its identification. On anti-tuberculous management, the patient was recovering. These indications were shown by the patient after execution of one month of antituberculous. It was an uncommon expression of the harmfulness of ethambutol. Its occurrence was reported as 1.52% according to one report [6]. After one month of management, its incidence is elevated. If it occurs regularly, the level of ALP is contributed to elevating after six months of management. This level may further elevate regularly if this therapy is carried out repeatedly [6]. Its incidence is negligible from the first year to 19 years of age [6]. Females between 30 -39 years of age are more vulnerable to it. So, cases having a high level of Alkaline Phosphate on ethambutol treatment are infrequent. This is the first case of fourteen years of age. He was not taking any medicines Lamivudine. Zidovudine. other Hydrocortisone Sodium Phosphate, Amikacin Sulphate, Ganciclovir are the major drugs which can lead to side effects [6]. This is only a case study reported so far [7, 8]. The pathway of such side effects of ethambutol is unrevealed. The factor that has been assigned to it is hypersensitivity [8]. While, after 2 months of therapy, there is a chance of occurrence of toxicity as reported in the previous studies [7, 8]. The time of improvement of the patient is comparable to a previous case study which is fifteen days and eleven days respectively.

CONCLUSION:

This case study was different as it was observed in younger age and there was a lower dose of cholestasis. The patient started indicating symptoms of cholestasis although he showed recovery at the start. Alkaline Phosphate level was sent for further examination. Along with alanine aminotransferase (ALT) which is common, ethambutol is included in anti-tuberculous therapy.

REFERENCES:

- eHealth Me Real World Drug Outcomes. Could Ethambutol hydrochloride cause Blood alkaline phosphatase increased? (Based on 19 reports from FDA and user community). Available from: <u>http://www.chcalthmc.com/ds/cthambutol</u> hydrochloride/blood+alkaline+phosphatase+incr eased.
- Mgulli Ford, A D Mackay, K Prowse, Cholestatic Jaundice caused by Ethambutol. BMJ. 1986.292:866.
- Ethambutol Overview. United States National Library of Medicine. Clinical and Research information on drug-induced liver disease. Retrieved from: Http://livertox. N ih.gov/Ethambutol.htm.
- 4. Marry Elizbeth, Milton Rossman Fishman. Clinical Presentation and Treatment of

Tuberculosis. Pulmonary Diseases and Disorders. Fourth Edition the McGraw-Hill, 2008.p.2478.

- Ayanniyi and Ayanniyi. A 37-year-old woman presenting with impaired visual function during antituberculosis drug therapy: a case report. Journal of Medical Case Reports 2011,5:317.
- Grace EM, Lee AG: Ocular Sarcoidosis: Ethambutol Toxicity and Optic Neuropathy: 60year-old female with bilateral painless central vision loss. Eyegrounds. org. Nov. 5, 2007; Available from http://www.Eye Rounds. Org/cases/75-Ethambutol Toxicity-Optic-Neuropathy.htm.
- Sajjad Ali, Uzma Usman, Muhammad Wasey. Rapidly developing Optic Neuritis secondary to Ethambutol: a possible mechanism of injury. JPMA July 2005.55(7)
- Lee EJ, Kim SJ, Choung HK, Kim JH, Yu YS. Incidence and clinical features of ethambutolinduced optic neuropathy in Korea. J Neuroophthalmological. 2008 Dec; 28(4):269-77.